Cancer immune resistance: can theories converge?

Area of Science:

• Oncology
• Immunology

Background:

• Immune oncology (IO) faces challenges in treating a wider range of cancers.
• Current checkpoint inhibitor therapy (CIT) has limitations in overcoming cancer immune resistance.
• Numerous models exist to explain resistance to CIT, but prevailing mechanisms remain unclear.

Purpose of the Study:

• To propose a simplified model for cancer immune resistance.
• To identify key evolutionary strategies employed by cancer cells to evade immune detection.
• To guide the development of next-generation IO agents targeting specific immune landscapes.

Main Methods:

• Review and synthesis of existing literature on cancer immune resistance.
• Conceptual modeling of tumor evolutionary pathways.
• Analysis of proposed immune-silent and immune-active tumor phenotypes.

Main Results:

• Cancer cells evolve through a conserved bottleneck with two primary evasion strategies.
• Option 1: Immune-silent tumors avoid immune detection by lacking immunogenic stimuli.
• Option 2: Immune-active tumors, while immunogenic, employ suppressive mechanisms to resist immune rejection.

Conclusions:

• Understanding these two fundamental evasion strategies is key to overcoming IO resistance.
• Targeting strategies for IO agents must be tailored to the specific immune landscape (silent vs. active).
• This framework may simplify the identification and targeting of resistance mechanisms, paving the way for broader IO application.